Premade Antibody Library Screening Services

Q: What formats can you deliver?

scFv, Fab, VHH, and reformatting to full-length IgG. We also support CAR-ready scFvs and ADC-suitable internalizers.

Premade Libraries Screening Services Cases Why Choose Us? FAQ

Fast-track antibody discovery with confidence. Long screening cycles, low hit rates, and complex workflows are slowing your program? Creative Biolabs' Premade Antibody Library Screening Service is your shortcut to rapid, high-quality hits. Our proprietary integration of best-in-class phage/yeast display with diversity-rich, validated premade libraries, plus our in-solution panning, orthogonal counter-selection, high-throughput analytics and NGS-guided enrichment, help us quickly and efficiently identify highly specific, high affinity, function-ready antibodies. We offer a one-stop, de-risked path from hit to lead so you can move your pipeline forward faster.

Get Started - Request Your Quote Today

Ready-to-Screen Antibody Libraries

Our premade antibody libraries span multiple species and formats, validated for high diversity and developability, and ready for rapid deployment.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Request a Custom Proposal

Premade Antibody Library Screening: Faster, Smarter Discovery

Creative Biolabs provides a wide range of premade, multi-species (human, mouse, camel, etc.) and multi-format (scFv, Fab, V_HH) antibody libraries to address your diverse discovery needs, from epitope-specific antibodies to cell-internalizing and multi-functional antibodies. We consistently succeed in challenging cases where target information is limited or epitopes are constrained and provide developable candidates with speed and confidence.

Ask About Turnaround & Pricing

Functional Human Antibody Discovery

End-to-end discovery of human scFv/Fab/V_HH binders with true functional activity (neutralization, agonism/antagonism, receptor blocking). We integrate phenotypic screening, epitope binning, and orthogonal assays early, ensuring hits translate into mechanism-relevant leads with strong developability profiles.

Anti-Peptide/Protein Antibody Discovery

Rapid isolation against linear peptides, conformational epitopes, recombinant proteins, or difficult antigens. Rational peptide design, scaffold presentation, and conformationally-biased panning to favor native-like binders while counter-selecting non-specific and constant-region interactors.

Anti-Cell-based Target Antibody Discovery

For membrane proteins and native conformations, we perform whole-cell panning (live/fixed) with stringent negative selection against parental/control cells. This enables discovery without purified antigen and enriches for binders recognizing the target in its physiological context.

Bi-functional Antibody Discovery

Discovery of bispecific precursors and dual-activity binders via dual-antigen toggling, sequential panning, and combinatorial display strategies. We focus on non-overlapping epitopes, balanced affinities, and manufacturability to help accelerate downstream formatting into BsAbs or multi-valent constructs.

Anti-Epitope Antibody Discovery

Precisely target known functional epitopes using competitive panning with reference antibodies or epitope-mimetic peptides. We use blocked/competitive elutions to bias libraries toward the same or adjacent epitope bins while preventing off-epitope enrichment.

Cell-Internalizing Antibody Discovery

Enrich for internalizers using temperature-shift panning, acid stripping, and intracellular capture assays. Ideal for receptor-mediated endocytosis targets and payload-delivery applications, enabling downstream ADC or targeted delivery programs.

Anti-Disease-Specific Target Antibody Discovery

Tailored campaigns against disease-relevant antigens (oncology, autoimmunity, infectious disease).

Antibody Discovery For Immunotherapy

Tailored for therapeutic areas like cancer treatment and immune regulation.

Case Study: High-Diversity Libraries, High-Impact Outcomes

Case 1: Type 1 and Type 2 Anti-Idiotypic Antibody Discovery via Premade Human scFv Library
Objective	Anti-idiotypic (anti-ID) antibodies, with preference for type 1 (blocking) and type 2 (non-blocking) that can recognize features of a therapeutic IgG's variable region.
	Type 1 Anti-Idiotype Antibody		Type 2 Anti-Idiotype Antibody

	Mimic the target antigen, blocking the original antibody's activity.		Bind without affecting the antibody's ability to bind its antigen.
Materials	Target IgG Isotype control IgG Antigen Protein	Strategy (In-solution)	Pre-counter selection with isotype control IgG to deplete constant-region binders Positive selection for biotinylated Target IgG. Competitive screening with isotype control to further deplete binders to constant regions. Elution with antigen to capture type 1 anti-ID. Antigen blocking plus acid buffer elution to enrich type 2 anti-ID.
Results	Significant enrichment over rounds of screening. Type 1 Anti-ID Antibodies Type 2 Anti-ID Antibodies Soluble functional ELISA confirmed anti-ID activity and segregated binders into type 1 and type 2. The purified binders were utilized as assay-ready reagents for PK/ADA method development and for mechanistic controls.

Submit the Request for Quote

Case 2: Screening for Same-Epitope Binders as a Positive Antibody via Premade Human Antibody Library
Objective	Identical epitope antibodies are targeted to support MOA replication and combination studies.
Materials	Target-huFc protein Control huFc protein Positive antibody	Strategy (in-solution)	Pre-counter selection with control huFc. Positive selection for biotinylated Target–huFc. Elution with the positive antibody to competitively release same-epitope binders.
Results	High levels of enrichment after 4 rounds. Eight candidates were identified by initial screen. Binding to the same epitope as the reference antibody was confirmed by competitive soluble scFv ELISA, which allowed orthogonal selection of candidates for downstream functional testing.

Why Choose Us?

Depth of Libraries

Broad, validated repertoires maximize epitope coverage and success across diverse target classes.

Precision Screening Design

In-solution and cell-based panning with rigorous counter-selection, blocked/competitive elutions, and epitope steering to align hits with your target.

Functional First

Early incorporation of phenotypic assays, internalization, competition, and kinetics delivers mechanism-relevant, developable antibodies.

Speed Without Compromise

Automated workflows, high thoughtput analytics, and reformatting-ready constructs reduce cycle times while preserving data integrity.

Transparent Partnership

Clear milestones, data-rich reports, optional NGS insights, and flexible IP terms under NDA.

From Hit to Lead

Seamless affinity maturation, epitope binning, cross-reactivity optimization, and IgG/CAR/ADC formatting on request.

Customize Your Package - Get Pricing

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

What inputs do you need to start?

Target details (species, existing format, sequence), intended application/MOA, any relevant antibodies, competitor antigens, desired species/format for output, and cell line if applicable for cell-based panning.

Can you work with difficult or unknown epitopes?

Yes. We employ competitive/blocked elutions, epitope-derived peptides, cell-based panning, and other strategies to bias toward the desired (usually native conformational) epitopes—even when the target structure is limited or unknown.

How fast is a typical campaign?

Initial binders are often delivered within 8 weeks depending on target complexity, screening mode, and analytics depth.

What deliverables will I receive?

Sequence-confirmed clones, binding/competition/internalization data as applicable, kinetics (BLI/SPR) when scoped, and reformatting-ready constructs. Optional NGS datasets are available.

Can you handle membrane proteins without purified antigen?

Yes. We offer whole-cell panning with stringent negative selection to enrich for physiologically relevant binders.

What formats can you deliver?

scFv, Fab, V_HH, and reformatting to full-length IgG. We also support CAR-ready scFvs and ADC-suitable internalizers.

How do you ensure developability?

Perform sequence liability checks and other filters early on. Provide optimization, maturation steps as needed.

What about IP and confidentiality?

Everything we discuss is covered by a signed NDA. IP terms are flexible and dependent on the scope of work. New sequences that we discover during a project are owned by the project owner.

Can you compare phage vs yeast display for my target?

Yes. We'll help recommend the best platform or a hybrid approach based on target class, epitope coverage needed, required assay readouts, and more.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: